Bayer on 09 June 2026 announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer's Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will report to Stefan Oelrich, Member of the Board of Management of Bayer AG and President of the company's Pharmaceuticals Division. Reinhard follows Nelson Ambrogio, who became President of Bayer U.S. Pharmaceuticals in May 2026.

Jost Reinhard is a seasoned global healthcare leader with more than 25 years of experience across research and development, commercial operations, and strategic leadership roles at Bayer. Currently serving as Head of Investor Relations at Bayer, he has played a central role in shaping the company's engagement with global capital markets during a pivotal moment for Bayer. Reinhard started his career in 2001 in Research & Development at Schering AG, which Bayer acquired in 2006, and held corporate roles in the company's Pharmaceuticals division before taking on commercial leadership positions of increasing responsibility in Australia, Poland, and France.

He later served as Head of Bayer's Cell and Gene Therapy unit, a key innovation area for the company, based in Boston, USA. Born in Traben-Trarbach, Germany, Reinhard studied pharmacy in Bonn, Germany, and Dijon, France, and earned his doctorate in molecular toxicology and medicinal chemistry from the German Cancer Research Center in Heidelberg. He is married with three daughters.